【摘要】：目的： NLRC5是一種具有強(qiáng)烈抗炎效應(yīng)的分子。本文通過生物信息學(xué)的方法，試圖篩選出NLRC5特異性多肽，并研究其在細(xì)胞水平和動(dòng)物水平的抗炎效應(yīng)。 方法： 1.通過生物信息學(xué)的方法篩選得到多肽LS22 運(yùn)用生物信息學(xué)原理,首先將篩選的序列用SMART軟件進(jìn)行多序列比對(duì),找出NLRC5蛋白的的保守序列。使用clustalx軟件對(duì)NLRCx蛋白的序列進(jìn)行同源比對(duì)，采用CLC Protein WorκBench軟件對(duì)NLRC5蛋白的親水性（Hydrophilicity）、抗原性（Anti-genicity）等物理特性進(jìn)行分析；最后從LRR序列中篩選出LS22。 2. LS22多肽體外抗炎效應(yīng)研究 通過MTS實(shí)驗(yàn)檢測(cè)LS22多肽對(duì)細(xì)胞活力的影響。通過脂多糖(LPS)分別刺激小鼠巨噬細(xì)胞Raw264.7，人臍靜脈上皮細(xì)胞HUVEC，人單核細(xì)胞THP-1來建立體外炎癥模型。通過ELISA和Q-PCR試驗(yàn)分別檢測(cè)加入不同濃度的LS22多肽對(duì)于LPS誘導(dǎo)的炎癥反應(yīng)的影響。并采用LPS誘導(dǎo)的趨化實(shí)驗(yàn)和TNF-α誘導(dǎo)的粘附實(shí)驗(yàn)來檢測(cè)LS22多肽是否也影響了細(xì)胞趨化反應(yīng)和粘附能力。 3. LS22多肽體內(nèi)抗炎效應(yīng)研究 采用LPS單次足墊注射法來誘導(dǎo)大鼠內(nèi)毒素誘導(dǎo)的葡萄眼（EIU）。將內(nèi)毒素溶于PBS中，使溶液濃度為2g/L，，將100μL內(nèi)毒素分別注射于實(shí)驗(yàn)組大鼠的雙后足底部；正常對(duì)照組后足底部僅注射100μL生理鹽水。隨后按分組將地塞米松、混雜序列肽、不同濃度LS22往大鼠雙眼玻璃體腔內(nèi)注射10μL；空白對(duì)照組和LPS組大鼠玻璃體腔內(nèi)僅注射PBS10μL。于注射前及注射后第24h進(jìn)行裂隙燈檢查，詳細(xì)記求臨床體征的改變。通過大鼠眼球活組織鏡檢，組織切片，EIU疾病打分，房水中浸潤細(xì)胞數(shù)目，房水總蛋白及細(xì)胞因子等不同的疾病特征，來檢測(cè)LS22體內(nèi)抗炎效應(yīng)。 4. LS22多肽抗炎機(jī)制研究 通過熒光素酶報(bào)告基因?qū)嶒?yàn)檢測(cè)LS22多肽對(duì)于LPS誘導(dǎo)的NF-kb信號(hào)通路活化的影響。通過共聚焦實(shí)驗(yàn)和免疫印記試驗(yàn)，檢測(cè)LS22多肽在RAW264.7細(xì)胞內(nèi)的作用位點(diǎn)及其對(duì)于LPS誘導(dǎo)的轉(zhuǎn)錄因子p65磷酸化及入核的影響。 結(jié)果： 1.多肽序列 通過上述方法，我們找到了與NLRC5的LRR結(jié)構(gòu)域類似的多肽LS22。其氨基酸序列為LDLSHNSISQESALYLLETLPS。 2. LS22多肽體外抗炎效應(yīng)研究 結(jié)果顯示，LS22多肽對(duì)于細(xì)胞活力無影響。不論從蛋白水平還是mRNA水平，對(duì)于檢測(cè)的三種細(xì)胞系，50μM、100μM的LS22多肽與陽性對(duì)照和混雜序列多肽組相比都，并且有劑量依賴關(guān)系，1μM無影響。LS22多肽抑制了LPS誘導(dǎo)的趨化反應(yīng)，但對(duì)TNF-α誘導(dǎo)的細(xì)胞粘附能力無影響。 3. LS22多肽體內(nèi)抗炎效應(yīng)研究 結(jié)果顯示，LS22多肽顯著抑制了臨床疾病特征。前房炎癥以及充血程度明顯降低，疾病打分減少。病理組織切片結(jié)果顯示LS22多肽顯著抑制了虹膜睫狀體部位和玻璃體后部視網(wǎng)膜區(qū)域炎癥細(xì)胞浸潤情況。房水中浸潤細(xì)胞數(shù)目減少，房水總蛋白降低，房水中炎癥因子TNF-α和IL-6水平也明顯下降。 4. LS22多肽抗炎機(jī)制研究 LS22多肽抑制了LPS誘導(dǎo)的NF-kb熒光素酶報(bào)告基因的活化。共聚焦實(shí)驗(yàn)和免疫印記實(shí)驗(yàn)顯示LS22多肽抑制p65的磷酸化及入核，但是對(duì)總p65無影響。 結(jié)論： 1.通過生物信息學(xué)手段，預(yù)測(cè)得到LS22多肽 2. LS22多肽在體外具有抑制炎癥的功能，并且具有劑量依賴效應(yīng) 3. LS22多肽具有抑制大鼠葡萄膜炎及體內(nèi)炎癥的功能 4. LS22多肽能抑制p65磷酸化及入核
[Abstract]:Purpose: NLRC5 is a fraction with a strong anti-inflammatory effect This paper, by means of bioinformatics, tries to screen the NLRC5-specific polypeptide and to study its anti-inflammatory effect at cell level and animal level. It is to be. Method: 1. Screening by means of bioinformatics In the application of the principle of bioinformatics, the polypeptide LS22 firstly uses the SMART software to carry out the multi-sequence comparison, and the NLRC5 egg is found out. The conserved sequence of NLRCx protein was compared with the sequence of NLRCx protein by using the clusalx software. The physical properties of NLRC5 protein, such as Hydrophilicity, Anti-genicity, were analyzed by using the CLC Protein Wor Benoch software, and finally from the LRR sequence. LS22. 2. LS22 filtered Study on the anti-inflammatory effect of polypeptide in vitro by MTS assay 2. The effect of the polypeptide on the cell viability. The mouse macrophage Raw264.7, human umbilical vein epithelial cell HUVEC and human monocyte THP were stimulated by lipopolysaccharide (LPS), respectively.-1 to establish an in vitro inflammatory model. LS22 polypeptides of different concentrations were detected for the LP by ELISA and Q-PCR assays, respectively. The effect of S-induced inflammatory response was investigated and the LPS-induced chemotaxis and TNF-induced adhesion experiments were used to detect whether the LS22 polypeptide has also been affected. Cell chemotaxis and adhesion. 3. The study of the anti-inflammatory effect of LS22 polypeptide in vivo was induced by LPS single-term foot pad injection method. The endotoxin-induced grape eye (EIU) was dissolved in PBS, the concentration of the solution was 2g/ L, and the 100 & mu; L endotoxin was injected into the bottom of the double-foot foot of the experimental group rats respectively; and after the normal control group, 100. m u.L of physiological saline was injected at the bottom of the foot. Dexamethasone, the mixed sequence peptide and the LS22 at different concentrations were then injected into the vitreous cavity of the rat with 10. m u.L in the group. In the blank control group and the LPS group, only PBS10.mu. L was injected into the vitreous cavity of the rat. The fracture was performed before and after the injection. The changes of clinical signs were found in the light examination and detailed records. The different diseases, such as the number of cells in the room, the total protein of the aqueous humor and the cytokines, were scored by the microscopic examination of the eye biopsy of the rat, the tissue section, the EIU disease, the number of infiltration cells in the room water, the total protein of the aqueous humor, and the cytokines. Sign, to detect the anti-inflammatory effect in LS22 The study of the anti-inflammatory mechanism of the polypeptide of the. 4. LS22 polypeptide through the luciferase reporter gene experiment to detect the LS22 polypeptide for L Effect of PS-induced activation of NF-kb signal pathway. The role of LS22 polypeptide in RAW264.7 cells and its effect on LPS were tested by co-focusing and imprints. induced transcription factor p6 5. Effect of Phosphorylation and Nucleation. Results: 1. The polypeptide sequence was obtained by the method described above. A polypeptide LS22 similar to the LRR domain of the NLRC5 is found. The sequence is LDLSHNSISQESA LYLLETLPS. 2.LS22 polypeptide body The results of the external anti-inflammatory effect show that the LS22 polypeptide has no effect on the cell viability. There was no effect on 1. m u.M and 1. m no effect on the LS22 polypeptide compared to the mixed-sequence polypeptide group. PS-induced chemotaxis, but for TNF-There was no effect on the ability of the cells to adhere to the cells. The results of the anti-inflammatory effect in the peptides show that the LS22 polypeptide The clinical features of the disease were significantly inhibited. The inflammation of the anterior chamber and the degree of hyperemia were significantly reduced, and the score of the disease was reduced. The results of the pathological tissue slice showed that the LS22 Polypeptides significantly inhibited the infiltration of inflammatory cells in the iris-ciliary body and in the posterior retinal region of the vitreous. The number of infiltration cells in the room was reduced. and the total protein of the aqueous humor is reduced, and the inflammation in the room water The levels of TNF-1 and IL-6 were also significantly decreased. The mechanism study the activation of the LPS-induced NF-kb luciferase reporter gene by the LS22 polypeptide. immunoprinting The results show that the LS22 polypeptide inhibits the phosphorylation and the in-in of p65. Nuclear, but no effect on total p65. Conclusion: 1. Bioinformatics and the LS22 polypeptide is predicted to have the LS22 polypeptide in vitro. the function of inhibiting inflammation and having a dose-dependent effect
【學(xué)位授予單位】：上海交通大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2014
【分類號(hào)】：R773.9

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周曉麗;;兒科膿毒癥診斷與治療的研究進(jìn)展[J];安徽醫(yī)學(xué);2011年11期

2 張磊;孫雯;解澤林;田野;;不同血管活性藥物治療腎移植術(shù)后感染性休克的臨床觀察[J];北京醫(yī)學(xué);2012年03期

3 孫婷;王曉芝;;連續(xù)性血液凈化與嚴(yán)重膿毒癥的治療[J];濱州醫(yī)學(xué)院學(xué)報(bào);2010年03期

4 王慧芬;蘇海濱;;肝衰竭的重癥監(jiān)護(hù)治療[J];傳染病信息;2009年05期

5 王宇明;湯影子;鄧國宏;晏澤輝;;肝衰竭合并癥研究進(jìn)展[J];傳染病信息;2010年02期

6 張沛生;龍濤;吳曉妹;白蓉蓉;李智;;血必凈注射液治療膿毒性休克[J];中國醫(yī)藥導(dǎo)刊;2008年04期

7 易紹東;阮云軍;龔志華;何建新;向定成;邱健;;銀丹心腦通軟膠囊治療高血壓患者合并腦梗死后遺癥的臨床觀察[J];中國醫(yī)藥導(dǎo)刊;2011年06期

8 林啟良;陳莜;劉軍;陳雯敏;;血清胱抑素C在嚴(yán)重膿毒血癥急性腎損傷的臨床應(yīng)用[J];中國醫(yī)藥導(dǎo)刊;2011年06期

9 張陽;陳莎;胡川閩;李淑慧;萬瑛;;抗hMIF單克隆抗體的活性鑒定及其對(duì)膿毒癥小鼠的保護(hù)作用[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2012年03期

10 馬洪;于向陽;周振理;;快通道外科研究進(jìn)展[J];腹部外科;2010年01期

相關(guān)會(huì)議論文 前10條

1 吳健鋒;歐陽彬;;感染性休克微循環(huán)障礙該縮血管還是擴(kuò)血管?[A];重癥醫(yī)學(xué)——2011[C];2011年

2 張宏民;劉大為;;心功能導(dǎo)向的急性呼吸窘迫綜合征肺保護(hù)性通氣策略[A];重癥醫(yī)學(xué)——2011[C];2011年

3 李孝建;鐘曉e

本文編號(hào)：2414920